Home › Companies › SILENCE THERAPEUTICS PLC › 2025-2026
At SILENCE THERAPEUTICS PLC's shareholder meeting held June 16, 2026, in the 2025-2026 proxy season, 51 asset managers reported how they voted in their SEC Form N-PX filings, covering 168 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — FOR was 99.8% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SILENCE THERAPEUTICS PLC's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and SILENCE THERAPEUTICS PLC’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 16, 2026: 8 items on SILENCE THERAPEUTICS PLC’s Form 8-K, filed June 16, 2026: 8 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore SILENCE THERAPEUTICS PLC in the interactive database Compare manager voting policies
These tallies are SILENCE THERAPEUTICS PLC’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| To re-appoint as a director of the Company James Ede-Golightly. | 52,112,045 | 605,683 | 4,680 | -- | -- | 99% | Not verified | — |
| To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. | 48,234,208 | 73,667 | 4,414,536 | -- | -- | 99.8% | Not verified | — |
| To ratify the appointment of PricewaterhouseCoopers LLP as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2026. | 52,718,407 | 2,885 | 1,119 | -- | -- | 99.9% | Not verified | — |
| To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. | 52,718,407 | 2,885 | 1,119 | -- | -- | 99.9% | Not verified | — |
| To authorize the Audit & Risk Committee to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2026. | 52,714,237 | 6,155 | 1,869 | -- | -- | 99.9% | Not verified | — |
| To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the "2025 U.K. | 52,715,076 | 3,108 | 4,077 | -- | -- | 99.9% | Not verified | — |
| To approve the directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 32 to 54 (inclusive) of the 2025 U.K. Annual Report. | 48,251,875 | 66,518 | 4,404,018 | -- | -- | 99.8% | Not verified | — |
| To approve the application of Article 159 of the Company's articles of association from the conclusion of this AGM to the conclusion of the next annual general meeting of the Company. | 48,307,317 | 9,333 | 4,405,761 | -- | -- | 99.9% | Not verified | — |
Source: SILENCE THERAPEUTICS PLC, Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.
Each item below shows how the 51 asset managers that disclosed a SILENCE THERAPEUTICS PLC vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of SILENCE THERAPEUTICS PLC’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To re-appoint James Ede-Golightly as a director, who retires in accordance with the articles of association
SILENCE THERAPEUTICS PLC’s own tally for this item (“Resolution 2 : To re-appoint as a director of the Company James Ede-Golightly.”): 52,112,045 for, 605,683 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 24,632 for, 158,453 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 0 | 156,253 | 0 | 0 | Against |
| State Street | 9,583 | 0 | 0 | 0 | For |
| Fidelity | 6,338 | 0 | 0 | 0 | For |
| STEWARD FUNDS, INC. | 5,800 | 0 | 0 | 0 | For |
| Invesco | 0 | 2,176 | 0 | 0 | Against |
| ProShares | 1,911 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,000 | 0 | 0 | 0 | For |
| TIAA | 0 | 24 | 0 | 0 | Against |
64% of fund votes cast · no official result
The 7 asset managers below reported 17,249 for, 9,583 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 0 | 9,583 | 0 | 0 | Against |
| Fidelity | 6,338 | 0 | 0 | 0 | For |
| STEWARD FUNDS, INC. | 5,800 | 0 | 0 | 0 | For |
| Invesco | 2,176 | 0 | 0 | 0 | For |
| ProShares | 1,911 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,000 | 0 | 0 | 0 | For |
| TIAA | 24 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To approve the application of Article 159 of the articles of association to the conclusion of the next annual general meeting of the Company
SILENCE THERAPEUTICS PLC’s own tally for this item (“Resolution 9 : To approve the application of Article 159 of the Company's articles of association from the conclusion of this AGM to the conclusion of the next annual general meeting of the Company.”): 48,307,317 for, 9,333 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 183,085 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 156,253 | 0 | 0 | 0 | For |
| State Street | 9,583 | 0 | 0 | 0 | For |
| Fidelity | 6,338 | 0 | 0 | 0 | For |
| STEWARD FUNDS, INC. | 5,800 | 0 | 0 | 0 | For |
| Invesco | 2,176 | 0 | 0 | 0 | For |
| ProShares | 1,911 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,000 | 0 | 0 | 0 | For |
| TIAA | 24 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2025
SILENCE THERAPEUTICS PLC’s own tally for this item (“Resolution 7 : To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the "2025 U.K.”): 52,715,076 for, 3,108 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 183,085 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 156,253 | 0 | 0 | 0 | For |
| State Street | 9,583 | 0 | 0 | 0 | For |
| Fidelity | 6,338 | 0 | 0 | 0 | For |
| STEWARD FUNDS, INC. | 5,800 | 0 | 0 | 0 | For |
| Invesco | 2,176 | 0 | 0 | 0 | For |
| ProShares | 1,911 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,000 | 0 | 0 | 0 | For |
| TIAA | 24 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement
SILENCE THERAPEUTICS PLC’s own tally for this item (“Resolution 3 : To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”): 48,234,208 for, 73,667 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of SILENCE THERAPEUTICS PLC’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, no shares for or against).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 156,253 | 0 | 0 | 0 | For |
| State Street | 9,583 | 0 | 0 | 0 | For |
| Fidelity | 6,338 | 0 | 0 | 0 | For |
| STEWARD FUNDS, INC. | 5,800 | 0 | 0 | 0 | For |
| Invesco | 2,176 | 0 | 0 | 0 | For |
| ProShares | 1,911 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,000 | 0 | 0 | 0 | For |
| TIAA | 24 | 0 | 0 | 0 | For |
Fund voting reports, all 8 managers: 183,085 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Siren, L.L.C. | 2,851,908 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 2,040,978 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 1,692,527 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 1,635,327 | 0 | 0 | 0 | For |
| Lombard Odier Asset Management (Europe) Ltd | 1,604,632 | 0 | 0 | 0 | For |
| Lombard Odier Asset Management (USA) Corp | 1,444,629 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 1,099,651 | 0 | 0 | 0 | For |
| Citadel | 987,750 | 0 | 0 | 0 | For |
| Tetragon Partners GP Ltd | 759,546 | 0 | 0 | 0 | For |
| 5AM Venture Management, LLC | 476,200 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 111,693 | 0 | 0 | 0 | For |
| M28 Capital Management LP | 101,203 | 0 | 0 | 0 | For |
| Point72 | 56,317 | 0 | 0 | 0 | For |
| FRED ALGER MANAGEMENT, LLC | 47,736 | 0 | 0 | 0 | For |
| BlackRock | 37,308 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 17,381 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 17,294 | 0 | 0 | 0 | For |
| Rhumbline | 13,923 | 0 | 0 | 0 | For |
| State Street | 9,584 | 0 | 0 | 0 | For |
| Two Sigma | 8,601 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 6,338 | 0 | 0 | 0 | For |
| GeoWealth Management, LLC | 5,335 | 0 | 0 | 0 | For |
| GAMMA Investing LLC | 4,883 | 0 | 0 | 0 | For |
| CIBC Private Wealth Group LLC | 4,331 | 0 | 0 | 0 | For |
| Renaissance | 3,841 | 0 | 0 | 0 | For |
Institutional-manager reports, all 42 managers: 15,046,688 for. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: TO APPROVE OUR DIRECTORS' REMUNERATION REPORT FOR THE YEAR ENDED DECEMBER 31, 2025, WHICH IS SET FORTH AS ANNEX A TO THE PROXY STATEMENT AND ON PAGES 32 TO 54 OF THE 2025 U.K. ANNUAL REPORT).
SILENCE THERAPEUTICS PLC’s own tally for this item (“Resolution 8 : To approve the directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 32 to 54 (inclusive) of the 2025 U.K. Annual Report.”): 48,251,875 for, 66,518 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 156,253 | 0 | 0 | 0 | For |
| State Street | 9,583 | 0 | 0 | 0 | For |
| Fidelity | 6,338 | 0 | 0 | 0 | For |
| STEWARD FUNDS, INC. | 5,800 | 0 | 0 | 0 | For |
| Invesco | 2,176 | 0 | 0 | 0 | For |
| ProShares | 1,911 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,000 | 0 | 0 | 0 | For |
| TIAA | 24 | 0 | 0 | 0 | For |
Fund voting reports, all 8 managers: 183,085 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Siren, L.L.C. | 2,851,908 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 2,040,978 | 0 | 0 | 0 | For |
| BlackRock | 37,308 | 0 | 0 | 0 | For |
| GeoWealth Management, LLC | 5,335 | 0 | 0 | 0 | For |
| GAMMA Investing LLC | 4,883 | 0 | 0 | 0 | For |
| Edward D. Jones & Co., L.P. | 2,500 | 0 | 0 | 0 | For |
| TRUIST FINANCIAL CORP | 437 | 0 | 0 | 0 | For |
| Wescott Financial Advisory Group, LLC | 400 | 0 | 0 | 0 | For |
| ENVESTNET ASSET MANAGEMENT INC | 174 | 0 | 0 | 0 | For |
| SmartHarvest Portfolios, LLC | 150 | 0 | 0 | 0 | For |
| Lido Advisors, LLC | 145 | 0 | 0 | 0 | For |
| ROCKEFELLER FINANCIAL LLC | 45 | 0 | 0 | 0 | For |
| Baird | 1 | 0 | 0 | 0 | For |
Institutional-manager reports, all 13 managers: 4,944,264 for.
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To authorize the Audit and Risk Committee to determine our U.K. statutory auditors' remuneration for the year ending December 31, 2026
SILENCE THERAPEUTICS PLC’s own tally for this item (“Resolution 6 : To authorize the Audit & Risk Committee to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2026.”): 52,714,237 for, 6,155 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 183,085 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 156,253 | 0 | 0 | 0 | For |
| State Street | 9,583 | 0 | 0 | 0 | For |
| Fidelity | 6,338 | 0 | 0 | 0 | For |
| STEWARD FUNDS, INC. | 5,800 | 0 | 0 | 0 | For |
| Invesco | 2,176 | 0 | 0 | 0 | For |
| ProShares | 1,911 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,000 | 0 | 0 | 0 | For |
| TIAA | 24 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP, as our U.S. independent registered public accounting firm for the year ending December 31, 2026
SILENCE THERAPEUTICS PLC’s own tally for this item (“Resolution 4 : To ratify the appointment of PricewaterhouseCoopers LLP as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2026.”): 52,718,407 for, 2,885 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 183,085 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 156,253 | 0 | 0 | 0 | For |
| State Street | 9,583 | 0 | 0 | 0 | For |
| Fidelity | 6,338 | 0 | 0 | 0 | For |
| STEWARD FUNDS, INC. | 5,800 | 0 | 0 | 0 | For |
| Invesco | 2,176 | 0 | 0 | 0 | For |
| ProShares | 1,911 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,000 | 0 | 0 | 0 | For |
| TIAA | 24 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To re-appoint PricewaterhouseCoopers LLP, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders
SILENCE THERAPEUTICS PLC’s own tally for this item (“Resolution 5 : To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.”): 52,718,407 for, 2,885 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 183,085 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 156,253 | 0 | 0 | 0 | For |
| State Street | 9,583 | 0 | 0 | 0 | For |
| Fidelity | 6,338 | 0 | 0 | 0 | For |
| STEWARD FUNDS, INC. | 5,800 | 0 | 0 | 0 | For |
| Invesco | 2,176 | 0 | 0 | 0 | For |
| ProShares | 1,911 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,000 | 0 | 0 | 0 | For |
| TIAA | 24 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 141,703,840 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 0.11% |
| 2 | State Street | <0.01% |
| 3 | Fidelity | <0.01% |
| 4 | STEWARD FUNDS, INC. | <0.01% |
| 5 | Invesco | <0.01% |
| 6 | ProShares | <0.01% |
| 7 | Blackstone Alternative Investment Funds | <0.01% |
| 8 | TIAA | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Siren, L.L.C. | 2.01% |
| 2 | GREAT POINT PARTNERS LLC | 1.44% |
| 3 | Redmile Group, LLC | 1.19% |
| 4 | Nantahala Capital Management, LLC | 1.15% |
| 5 | Lombard Odier Asset Management (Europe) Ltd | 1.13% |
| 6 | Lombard Odier Asset Management (USA) Corp | 1.02% |
| 7 | ADAR1 Capital Management, LLC | 0.78% |
| 8 | Citadel | 0.70% |
| 9 | Tetragon Partners GP Ltd | 0.54% |
| 10 | 5AM Venture Management, LLC | 0.34% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Richard Griffiths | 10.16% | 13D |
| FMR LLC | 9.30% | 13G |
| Robert Keith | 8.67% | DEF14A |
| Raymond Debbane | 7.01% | 13G |
| Tetragon Financial Group Limited | 6.97% | 13G |
| TCG Crossover Fund I, L.P. | 6.42% | DEF14A |
| Invus Public Equities Advisors, LLC | 6.16% | DEF14A |
| Lombard Odier Asset Management (USA) Corp | 4.19% | 13G |
| Craig Tooman | 2.69% | DEF14A |
| Iain Ross | 1.20% | DEF14A |
Percentages above are of 141,703,840 shares outstanding, as reported by SILENCE THERAPEUTICS PLC on its Form 10-Q dated April 30, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SILENCE THERAPEUTICS PLC’s 10-Q dated April 30, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
SILENCE THERAPEUTICS PLC proxy season coverage: 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “SILENCE THERAPEUTICS (SLN) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/silence-therapeutics-plc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.